The molecular epidemiology of carbapenem-resistant Citrobacter freundii in Lishui City
-
摘要:
目的 分析碳青霉烯耐药弗劳地枸橼酸杆菌(CRCF)的耐药机制和分子流行病学特征,为抗感染诊治提供实验室依据。 方法 收集丽水市中心医院2016年1月—2022年12月分离的共17株CRCF菌株,采用微量肉汤稀释法检测MIC值,通过PCR法检测碳青霉烯酶基因(blaKPC-2、blaNDM-1、blaIMP-1、blaVIM-1、blaOXA-48)及遗传背景;利用接合转化实验分析质粒转移性和质粒类型;采用MLST法确定分型,结合Pubmed数据库菌株数据进行系统发育分析。 结果 17株CRCF对复方新诺明的耐药率为100%(17/17),对头孢他啶、头孢吡肟、氨曲南的耐药率均为76.5%(13/17),对美罗培南的耐药率为82.4%(14/17),对亚胺培南的耐药率为64.7%(11/17),对哌拉西林/他唑巴坦的耐药率为94.1%(16/17),对LVX的耐药率为58.8%(10/17),对阿米卡星的耐药率为47.1%(8/17),对多粘菌素B的耐药率为11.8%(2/17),对替加环素的耐药率最低,仅为5.9%(1/17)。11株菌携带blaNDM-1,5株携带blaKPC-2, 1株携带blaIMP-4。54.5%(6/11)的blaNDM-1位于IncX3质粒;blaKPC-2均位于IncFⅡ质粒。菌株分属于14种ST型,系统发育分析显示散发。 结论 丽水市CRCF对碳青霉烯类抗生素高度耐药,主要携带blaNDM-1和blaKPC-2,呈现散发流行。 -
关键词:
- 碳青霉烯耐药弗劳地枸橼酸杆菌 /
- 耐药机制 /
- 耐药性 /
- 多位点序列分型 /
- IncX3质粒
Abstract:Objective To analyze the resistance mechanisms and molecular epidemiological characteristics of carbapenem-resistant Citrobacter freundii (CRCF), providing laboratory evidence for clinical prevention and treatment. Methods CRCF strains collected from January 2016 to December 2022 in Lishui Central Hospital were tested for MIC using the broth microdilution method. PCR was employed to detect carbapenemase genes (blaKPC-2, blaNDM-1, blaIMP-1, blaVIM-1, blaOXA-48), and the genetic background of resistance genes. Conjugation and transformation experiments were conducted to analyze plasmid transferability and plasmid typing. MLST typing was combined with CRCF strains from the PubMed database for phylogenetic analysis. Results The resistance rates of 17 CRCF isolates were 100% (17/17) to trimethoprim/sulfamethoxazole; 76.5% (13/17) to ceftazidime, cefepime, and aztreonam; 82.4% (14/17) to meropenem; 64.7% (11/17) to imipenem; 94.1% (16/17) to piperacillin/tazobactam; 58.8% (10/17) to LVX; 47.1% (8/17) to amikacin; 11.8% (2/17) to polymyxin; and the lowest resistance rate was to tigecycline at 5.9% (1/17). Among these strains, 11 carried blaNDM-1, 5 carried blaKPC-2, and 1 carried blaIMP-4. 54.5%(6/11)of blaNDM-1 were located on IncX3 plasmids, while all of blaKPC-2 were located on IncFⅡ plasmids. The strains were classified into 14 ST types, with phylogenetic analysis indicating sporadic distribution. Conclusion CRCF in Lishui exhibits high resistance to carbapenem antibiotics, primarily carrying blaNDM-1 and blaKPC-2, presenting a sporadic epidemic pattern. -
表 1 质粒不相容群分型检测引物
Table 1. Primers for plasmid incompatibility group typing detection
目的基因 引物名称 引物序列 产物大小(bp) 参考序列 IncFⅡ UTF TTTACACCTGGCCGCCTGAA 497 pFOS18(KJ653815) UTR GCGCCCAGATGTACCATGAG IncⅠ IF AGATCCGTTTCTGGGAAGAC 574 pKPC-LKEc(KC788405) IR GGTGTTATCCAGACGTAACG IncR RF AAGCTGGATGTCAACAGCGC 775 pSg1-2(CP012428) RR AATGCACGCTGAAGTAGGTG IncQ QF CTATCGACATTCTGGCGAGC 632 pPH18(KU644672) QR GGTCATACCGGAGAGGTATG IncU UF CAGCCATCCATCATGGTCTA 720 pHP2(KU644677) UR CTGGAATAGGTTGATCAGCG IncX3 X3F TCGTGAAGACAGTAACGGGA 765 pNDM-HN380(JX104760) X3R CAAATCTAAGCATGTGAGCC 注:质粒不相容群分型检测引物见参考文献报道[12]。 表 2 CRCF株临床信息、ST型、质粒类型、携带耐药基因以及碳青霉烯酶类型
Table 2. Clinical information of CRCF strain, ST type, plasmid type, carried resistance genes, and carbapenemase type
菌株 科室分布 标本类型 ST型 质粒类型 耐药基因 mCIM eCIM 碳青霉烯酶类型 CRCF01 神经内科 痰液 ST129 IncFⅡ blaKPC-2 阳性 阴性 丝氨酸碳青霉烯酶 CRCF02 心内科 痰液 ST937 IncFⅡ blaKPC-2 阳性 阴性 丝氨酸碳青霉烯酶 CRCF03 康复科 尿液 ST299 IncN1 blaIMP4 阳性 阳性 金属β-内酰胺酶 CRCF04 消化内科 胆汁 ST91 IncX3 blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF05 泌尿外科 尿液 ST116 IncX3 blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF06 泌尿外科 尿液 ST116 IncFⅡ blaKPC-2 阳性 阴性 丝氨酸碳青霉烯酶 CRCF07 血液内科 痰液 ST103 IncFⅡ blaKPC-2 阳性 阴性 丝氨酸碳青霉烯酶 CRCF08 介入科 脓液 ST396 - blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF09 泌尿外科 尿液 ST344 IncX3 blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF10 康复医学科 尿液 ST63 IncF blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF11 妇产科 尿液 ST22 IncX3 blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF12 肝胆胰外科 胆汁 ST91 - blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF13 呼吸内科 痰液 ST22 - blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF14 血液内科 全血 ST532 IncFⅡ blaKPC-2 阳性 阴性 丝氨酸碳青霉烯酶 CRCF15 心胸外科 脓液 ST186 - blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF16 康复医学科 尿液 ST589 IncX3 blaNDM-1 阳性 阳性 金属β-内酰胺酶 CRCF17 重症医学科 肛拭子 ST552 IncX3 blaNDM-1 阳性 阳性 金属β-内酰胺酶 注:-表示多次转化、接合未能分离到碳青霉烯耐药质粒,故不能确定质粒分型。 表 3 CRCF菌株药敏检测结果(MIC, μg/mL)
Table 3. Antimicrobial susceptibility test results of CRCF strains (MIC, μg/mL)
菌株 CAZ FEP ATM IPM MEM TZP AMK POL TGC LVX SXT CRCF01 8 2 64 2 1 128/4 ≤4 0.5 0.25 4 ≥64/1 216 CRCF02 8 4 64 4 4 256/4 ≤4 0.5 1 0.25 ≥64/1 216 CRCF03 ≥256 ≥256 ≥256 2 4 ≥1 024/4 ≥1 024 0.5 32 16 ≥64/1 216 CRCF04 ≥256 ≥256 ≥256 ≥128 ≥128 ≥1 024/4 ≥1 024 32 0.25 32 ≥64/1 216 CRCF05 ≥256 ≥256 ≥256 16 32 ≥1 024/4 ≥1 024 2 0.25 64 ≥64/1 216 CRCF06 16 64 ≥256 ≥64 16 128/4 ≥1 024 0.5 0.5 1 ≥64/1 216 CRCF07 4 4 32 2 2 128/4 ≥1 024 0.5 0.25 4 ≥64/1 216 CRCF08 ≥256 ≥256 ≥256 ≥64 ≥64 ≥1 024/4 ≤4 0.5 0.5 1 ≥64/1 216 CRCF09 ≥256 32 ≤1 16 16 256/4 8 2 0.25 1 ≥64/1 216 CRCF10 ≥256 64 4 8 8 ≥1 024/4 ≥1 024 2 0.25 4 ≥64/1 216 CRCF11 ≥256 ≥256 32 4 4 256/4 ≤4 0.5 0.25 2 ≥64/1 216 CRCF12 ≥256 64 128 16 32 512/4 ≤4 0.5 0.25 16 ≥64/1 216 CRCF13 ≥256 16 ≤1 4 4 256/4 ≤4 0.5 0.25 8 ≥64/1 216 CRCF14 8 8 128 2 4 256/4 ≤4 0.5 1 0.5 ≥64/1 216 CRCF15 ≥256 128 32 16 ≥64 ≥1 024/4 ≤4 0.5 0.5 1 ≥64/1 216 CRCF16 ≥256 32 ≥256 0.5 2 4/4 32 ≥64 0.125 1 ≥64/1 216 CRCF17 ≥256 32 ≤1 2 4 512/4 ≥1 024 0.5 0.25 2 ≥64/1 216 敏感MIC ≤4 ≤2 ≤4 ≤1 ≤1 ≤8/4 ≤4 ≤2 ≤0.5 ≤2/38 中介MIC 8 4~8 8 2 2 8 2 4 1 4/76 耐药MIC ≥16 ≥16 ≥16 ≥4 ≥4 ≥32/4 ≥16 ≥4 ≥8 ≥2 ≥8/152 -
[1] 朱玉, 张龙, 魏取好. 弗劳地枸橼酸杆菌的临床分布及其耐药性分析[J]. 齐齐哈尔医学院学报, 2022, 43(12): 1109-1113.ZHU Y, ZHANG L, WEI Q H. Clinical distribution and drug resistance analysis of Citrobacter freundii[J]. Journal of Qiqihar Medical University, 2022, 43(12): 1109-1113. [2] 杜娜, 李焕芹, 刘淑敏, 等. 碳青霉烯类耐药弗劳地枸橼酸杆菌耐药及毒力基因的分析[J]. 微生物学免疫学进展, 2021, 49(1): 17-22.DU N, LI. H Q, LIU S M, et al. Analysis of drug resistance and virulence genes of carbapenem-resistant Citrobacter freundii[J]. Advances in Microbiology and Immunology, 2021, 49(1): 17-22. [3] 黄蓉, 段小女, 芮勇宇. 多重耐药弗劳地枸橼酸杆菌的基因组及耐药机制分析[J]. 国际检验医学杂志, 2024, 45(7): 785-789.HUANG R, DUAN X N, RUI Y Y. Genomic and drug resistance mechanism analysis of multidrug-resistant Citrobacter freundii[J]. International Journal of Laboratory Medicine, 2024, 45(7): 785-789. [4] 任建伟, 朱光发. 碳青霉烯类耐药肠杆菌目细菌的耐药机制与快速检测[J]. 心肺血管病杂志, 2023, 42(10): 1087-1091.REN J W, ZHU G F. Drug resistance mechanism and rapid detection of carbapenem-resistant Enterobacteriaceae[J]. Journal of Cardiovascular and Pulmonary Diseases, 2023, 42(10): 1087-1091. [5] 武亚鑫, 赵敏, 李浩然. 耐碳青霉烯肺炎克雷伯菌流行现状、耐药机制及抗菌药物诊疗进展[J]. 长春中医药大学学报, 2023, 39(1): 96-103.WU Y X, ZHAO M, LI H R. Current status of carbapenem-resistant Klebsiella pneumoniae, drug resistance mechanism and progress in antimicrobial treatment[J]. Journal of Changchun University of Traditional Chinese Medicine, 2023, 39(1): 96-103. [6] 李凤妍, 严茹钰, 曹小利. 肺炎克雷伯菌碳青霉烯酶研究进展[J]. 临床检验杂志, 2023, 41(9): 684-687.LI F Y, YAN R Y, CAO X L. Research progress of carbapenemase in Klebsiella pneumoniae[J]. Journal of Clinical Laboratory, 2023, 41(9): 684-687. [7] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: CLSI M100[S]. Wayne, PA: Clinical and Laboratory Standards Institute, 2021. [8] 胡玉明, 李娟. mCIM联合eCIM检测产碳青霉烯酶肠杆菌科细菌的临床应用[J]. 中华预防医学杂志, 2021, 55(4): 506-511.HU Y M, LI J. Clinical application of mCIM and eCIM combined detection of carbapenemase-producing enterobacteriaceae[J]. Chinese Journal of Preventive Medicine, 2021, 55(4): 506-511. [9] COSKUN U S S, CALISKAN E, CICEK A C, et al. β-lactamase genes in carbapenem resistance Acinetobacter baumannii isolates from a Turkish university hospital[J]. J Infect Dev Ctries, 2019, 13(1): 50-55. doi: 10.3855/jidc.10556 [10] ZHAO D, GAO F, GUAN P, et al. Identification and analysis of differentially expressed trihelix genes in maize (Zea mays) under abiotic stresses[J]. Peer J, 2023, 11: e15321. DOI: 10.7717/peerj.15321. [11] XIAO S, TANG C, ZENG Q, et al. Antimicrobial resistance and molecular epidemiology of Escherichia coli from bloodstream infection in Shanghai, China, 2016-2019[J]. Front Med (Lausanne), 2021, 8: 803837. DOI: 10.3389/fmed.2021.803837. [12] LI P, LUO W Y, XIANG T X, et al. Isolation of Hv-CRKP with co-production of three carbapenemases (blaKPC, blaOXA-181 or OXA-232, and blaNDM-1) and a virulence plasmid: a study from a Chinese tertiary hospital[J]. Front Microbiol, 2023, 14: 1182870. DOI: 10.3389/fmicb.2023.1182870. [13] 兰敏, 赵志军, 康宇婷, 等. 耐碳青霉烯类肠杆菌目细菌分子流行病学特征及耐药性[J]. 中国感染控制杂志, 2022, 21(11): 1053-1059.LAN M, ZHAO Z J, KANG Y T, et al. Molecular epidemiological characteristics and drug resistance of carbapenem-resistant Enterobacteriaceae[J]. Chinese Journal of Infection Control, 2022, 21(11): 1053-1059. [14] 马雪娇, 程君, 胡立芬, 等. 临床分离弗劳地枸橼酸杆菌耐药性分析及质粒介导的AmpC酶基因检测[J]. 安徽医学, 2019, 40(9): 966-970.MA X J, CHENG J, HU L F, et al. Drug resistance analysis of clinical isolated Citrobacter freundii and detection of plasmid-mediated AmpC enzyme gene[J]. Anhui Medical Journal, 2019, 40(9): 966-970. [15] DZIRI R, KUSKUCU M A, ARFAOUI A, et al. Whole genome sequencing of a Citrobacter freundii strain isolated from the hospital environment: an extremely multiresistant NDM-1 and VIM-48 coproducing isolate[J]. Microb Drug Resist, 2022, 28(1): 18-22. doi: 10.1089/mdr.2020.0417 [16] QIAO J, CHEN Y, GE H, et al. Coexistence of blaIMP-4, blaNDM-1 and blaOXA-1 in blaKPC-2-producing Citrobacter freundii of clinical origin in China[J]. Front Microbiol, 2023, 14: 1074612. DOI: 10.3389/fmicb.2023.1074612. [17] 陈建飞, 方寅飞, 徐浩. 耐碳青霉烯类弗劳地枸橼酸杆菌致医院获得性感染的临床特征与耐药性分析[J]. 中国消毒学杂志, 2022, 39(4): 282-285.CHEN J F, FANG Y F, XU H. Clinical characteristics and drug resistance analysis of carbapenem-resistant Citrobacter freundii causing hospital-acquired infections[J]. Chinese Journal of Disinfection, 2022, 39(4): 282-285. [18] 弗林迪, 方颍, 张嵘, 等. 弗劳地枸橼酸杆菌中质粒介导的KPC-2和NDM-1型碳青霉烯酶基因结构分析[J]. 临床检验杂志, 2016, 34(6): 423-427.FU L D, FANG Y, ZHANG R, et al. Analysis of plasmid-mediated KPC-2 and NDM-1 carbapenemase gene structures in Citrobacter freundii[J]. Journal of Clinical Laboratory, 2016, 34(6): 423-427. [19] 郭燕, 胡付品, 朱德妹, 等. 2023年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2024, 24(6): 627-637.GUO Y, HU F P, ZHU D M, et al. Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET Antimicrobial Resistance Surveillance Program, 2023[J]. Chinese Journal of Infection and Chemotherapy, 2024, 24(6): 627-637. [20] WANG Q, DONG K, LIU X, et al. Genetic characteristics of chromosomally integrated carbapenemase gene blaNDM-1 in isolates of Proteus mirabilis[J]. BMC Microbiol, 2024, 24(1): 216. DOI: 10.1186/s12866-024-03274-9. [21] TOUATI A, MANSEUR L, MEHIDI I, et al. Epidemiological and genetic features of plasmids carrying blaNDM genes: an in silico analysis with emphasis on replicon types, and resistome[J]. Microb Drug Resist, 2021, 27(9): 1232-1242. doi: 10.1089/mdr.2020.0427 [22] 史杨, 彭莉蓉, 黄建胜, 等. 产新德里金属β-内酰胺酶大肠埃希菌的耐药机制及分子流行病学研究[J]. 中华全科医学, 2019, 17(10): 1640-1643. doi: 10.16766/j.cnki.issn.1674-4152.001017SHI Y, PENG L R, HUANG J S, et al. Resistance mechanism and molecular epidemiology of Escherichia coli producing new delhi metal β-lactamase[J]. Chinese Journal of General Practice, 2019, 17(10): 1640-1643. doi: 10.16766/j.cnki.issn.1674-4152.001017 [23] CEJAS D, MAGARIÑOS F, ELENA A, et al. Emergence and clonal expansion of Klebsiella pneumoniae ST307, simultaneously producing KPC-3 and NDM-1[J]. Rev Argent Microbiol, 2022, 54(4): 288-922. -
下载: